Friday, July 3, 2020
Thursday, June 25, 2020
Published on the MassGeneral website, I am including the full text below. This is part 1.
Tuesday, June 23, 2020
In their own words:
Join us (virtually) September 29 – October 2!
The global pandemic may have upended our original plans but it can’t stop us from uniting the ovarian cancer community from all over the world. The format may be different (no in-person hugs) but we promise to provide the same eye-opening, educational content from the country’s top researchers and doctors about every aspect of ovarian cancer, including treatment, wellness, advocacy and survivorship, as we always have but this time with a few surprises.
While we’re undeniably disappointed that we won’t be able to see everyone in person, there is a significant up-side to moving our conference online: Now anyone who wants to attend will have the chance, no travel necessary! We’re excited to expand our strong and welcoming community to reach even more people with important updates in the ovarian cancer field and OCRA’s patient support programs.
Past attendees have said that this conference is a can’t miss event for the ovarian cancer community: a gathering of hope, inspiration, new found knowledge and sisterhood.
We are excited for you to join us!
To register, follow this link.
Monday, June 22, 2020
Olaparib (Lynparza) is only approved for women with germline BRCA mutations.
PARP inhibitors work by preventing cancer cells from repairing their DNA damage caused by previous anticancer medications.
Despite FDA approval for front-line therapy after platinum based chemo, the side effects may make the drug intolerable for some women. These include anemia, neutropenia, GI toxicity and fatigue.
To read more about Nirapamib's approval, follow this link.